结节病免疫抑制剂与TNF抑制剂的不良反应比较:真实世界数据分析
本研究基于TriNetX数据库2012-2023年82家医疗机构的结节病患者数据,采用倾向性评分匹配比较二线药物(免疫抑制剂)和TNF抑制剂1年内严重不良反应风险。结果显示,与甲氨蝶呤相比,吗替麦考酚酯增加住院、重症监护、机械通气、死亡和感染风险,硫唑嘌呤增加死亡、血液毒性和感染风险;英夫利西单抗与阿达木单抗严重不良反应发生率相似,但英夫利西单抗贫血、血小板减少和肺炎风险略高,皮肤软组织感染风险较低。
要点
- 与甲氨蝶呤相比,吗替麦考酚酯增加住院、重症监护、机械通气、死亡和感染风险。
- 硫唑嘌呤较甲氨蝶呤增加死亡、血液毒性和感染风险。
- 英夫利西单抗与阿达木单抗严重不良反应相似,但贫血、血小板减少和肺炎风险略高。
核心结论
- 与甲氨蝶呤相比,吗替麦考酚酯增加感染和骨髓抑制等严重不良反应风险。
- 英夫利西单抗与阿达木单抗的严重不良反应发生率相似。
研究设计与样本
- 回顾性分析TriNetX研究网络2012-2023年82家医疗机构的结节病患者数据。
- 采用倾向性评分匹配控制混杂因素。
- 免疫抑制剂组共13,814例,TNF抑制剂组共3,964例。
主要发现
- 与甲氨蝶呤相比,吗替麦考酚酯住院风险HR 2.74(95%CI 2.11-3.56),重症监护风险HR 2.37(95%CI 1.91-2.94),机械通气风险HR 4.04(95%CI 2.630-6.21),死亡风险HR 2.16(95%CI 1.70-2.75),感染风险亦增加。
- 与甲氨蝶呤相比,硫唑嘌呤增加死亡、血液毒性和感染风险。
- 英夫利西单抗组较阿达木单抗组贫血风险HR 1.81(95%CI 1.22-2.67),血小板减少风险HR 2.67(95%CI 1.75-4.07),肺炎风险HR 1.47(95%CI 1.02-2.10),皮肤软组织感染风险HR 0.39(95%CI 0.17-0.89)。
临床怎么用
- 选择结节病二线免疫抑制剂时需权衡吗替麦考酚酯和硫唑嘌呤的感染及骨髓抑制风险。
- 英夫利西单抗与阿达木单抗严重不良反应相似,但英夫利西单抗需关注贫血、血小板减少和肺炎风险。
局限性
- 回顾性研究设计可能存在残余混杂。
- 数据来源于电子病历,可能存在信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcoidosis is a complex systemic granulomatous disease with varying clinical manifestations, and immunosuppressive agents and tumor necrosis factor (TNF) inhibitors have been used in severe and refractory cases. However, the comparison of the serious side effects of these treatments remains poorly understood. RESEARCH QUESTION: In sarcoidosis, what is the 1-year risk of serious side effects among second-line agents (immunosuppressants) and TNF inhibitors? STUDY DESIGN AND METHODS: A retrospective analysis of data from the TriNetX Research Network, which includes de-identified medical records of patients with sarcoidosis treated with specific immunosuppressive agents or TNF inhibitors between 2012 and 2023 across 82 health care organizations. Propensity score matching (PSM) was used to mitigate confounding effects. RESULTS: A total of 13,814 patients receiving immunosuppressive agents were included. We found that patients who received mycophenolate mofetil (MMF) showed higher risks for inpatient hospitalization (hazard ratio [HR], 2.74; 95% CI, 2.11-3.56), critical care (HR, 2.37; 95% CI, 1.91-2.94), mechanical ventilation (HR, 4.04; 95% CI, 2.630-6.21), mortality (HR, 2.16; 95% CI, 1.70-2.75), and infections compared with those who received methotrexate. Azathioprine use showed increased risks for mortality, hematologic toxicity, and infections compared with methotrexate use. Among the 3,964 patients with sarcoidosis receiving TNF inhibitors, we found similar rare occurrence of serious side effects between infliximab and adalimumab, although a slightly higher risk of anemia (HR, 1.81; 95% CI, 1.22-2.67), thrombocytopenia (HR, 2.67; 95% CI, 1.75-4.07), and pneumonia (HR, 1.47; 95% CI, 1.02-2.10), but lower risk of skin soft tissue infection (HR, 0.39; 95% CI, 0.17-0.89) in the infliximab group. INTERPRETATION: We used large real-world data with a PSM approach to demonstrate the heightened risk of infection and bone marrow suppression with MMF compared with the other immunosuppressants and a similar rate of serious side effects between infliximab and adalimumab.
引用
- Chao WC, Liao SY. Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis: A Real-World Data Analysis. Chest. 2025. PMID: 41077383. doi:10.1016/j.chest.2025.09.130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。